CMC Biologics Expands GMP Manufacturing Capacity in the United States and Europe
Company plans to add more than 30,000L of bioreactor capacity across its three sites
11-May-2015
- Denmark
CMC Biologics, Inc announced a plan to expand its global manufacturing capacity by more than 30,000 liters in the United States and Europe to meet growing customer demands for late-stage and commercial manufacturing.
"This global expansion addresses increasing demands from our customers for late-stage and commercial manufacturing," said Gustavo Mahler, PhD, Global Chief Operations Officer of CMC Biologics. "CMC Biologics is investing in innovative facility design to provide the production flexibility needed to meet aggressive regulatory and production timelines and speed our customers' products to market."
Other news from the department research and development
